BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy

Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combination can in...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of ovarian research Vol. 16; no. 1; pp. 231 - 16
Main Authors:	Farokhi Boroujeni, Salar, Rodriguez, Galaxia, Galpin, Kristianne, Yakubovich, Edward, Murshed, Humaira, Ibrahim, Dalia, Asif, Sara, Vanderhyden, Barbara C.
Format:	Journal Article
Language:	English
Published:	London BioMed Central 28.11.2023 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Analysis Angiogenesis Animals B7-H1 Antigen - genetics BRCA mutations BRCA1 protein BRCA1 Protein - genetics BRCA2 protein BRCA2 Protein - genetics Breast cancer Cancer Cancer therapies Care and treatment Cell death Clinical trials DNA damage DNA repair Female Genes, BRCA2 Genomes Gynecology Humans Immune checkpoint inhibitors Immunomodulation Immunotherapy Inflammation Medical prognosis Medicine Medicine & Public Health Mice Monoclonal antibodies Mutation Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism PARP inhibitors PD-L1 protein Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Reproductive Medicine RNA Survival Tumor microenvironment Tumor Microenvironment - genetics Tumors Immune checkpoint inhibitors mutations PARP inhibitors Ovarian cancer BRCA mutations
ISSN:	1757-2215, 1757-2215
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!